Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Targeting MAPK pathway in mutant BRAF melanoma with the specific BRAF inhibitor vemurafenib showed robust initial responses in the majority of patients followed by relapses due to acquired resistance to the drug. In (V600E)BRAF melanoma cell lines, senescence-associated β-galactosidase activity is o...

Descripción completa

Detalles Bibliográficos
Autores principales: Krayem, Mohammad, Najem, Ahmad, Journe, Fabrice, Morandini, Renato, Sales, François, Awada, Ahmad, Ghanem, Ghanem E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112757/
https://www.ncbi.nlm.nih.gov/pubmed/30159130
http://dx.doi.org/10.18632/oncotarget.25879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112757/
https://www.ncbi.nlm.nih.gov/pubmed/30159130
http://dx.doi.org/10.18632/oncotarget.25879

Ejemplares similares